Merck &Co. drops osteoporosis drug odanacatib.
Asher
A
Mullard
D001713:Biphenyl Compounds / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use; D056657:Cathepsin K / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D004345:Drug Industry / Q000639:trends*; D006801:Humans; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy*
D001713:Biphenyl Compounds; D050071:Bone Density Conservation Agents; C534130:CTSK protein, human; D056657:Cathepsin K; C527128:odanacatib